Rigel enrolls first patient in phase 3 clinical trial of fostamatinib disodium hexahydrate
Rigel announced it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia. The trial protocol calls for 80 patients in a 24-week study with topline results projected for early 2021. May 16, 2019